JP2017523805A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523805A5 JP2017523805A5 JP2017523183A JP2017523183A JP2017523805A5 JP 2017523805 A5 JP2017523805 A5 JP 2017523805A5 JP 2017523183 A JP2017523183 A JP 2017523183A JP 2017523183 A JP2017523183 A JP 2017523183A JP 2017523805 A5 JP2017523805 A5 JP 2017523805A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- lcdr
- hcdr
- antibody
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 77
- 239000000427 antigen Substances 0.000 claims description 73
- 102000036639 antigens Human genes 0.000 claims description 73
- 108091007433 antigens Proteins 0.000 claims description 73
- 241000713196 Influenza B virus Species 0.000 claims description 26
- 101710154606 Hemagglutinin Proteins 0.000 claims description 18
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 18
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 18
- 101710176177 Protein A56 Proteins 0.000 claims description 18
- 239000000185 hemagglutinin Substances 0.000 claims description 18
- 230000003472 neutralizing effect Effects 0.000 claims description 15
- 208000037798 influenza B Diseases 0.000 claims description 14
- 101900234398 Influenza B virus Hemagglutinin Proteins 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 241000712431 Influenza A virus Species 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 208000037797 influenza A Diseases 0.000 claims description 8
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 238000003556 assay Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 241000713174 Influenza B virus (B/Ann Arbor/1/1966 [wild- type]) Species 0.000 claims description 2
- 241000831652 Salinivibrio sharmensis Species 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000009977 dual effect Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 241000712461 unidentified influenza virus Species 0.000 claims 3
- 235000001630 Pyrus pyrifolia var culta Nutrition 0.000 claims 1
- 240000002609 Pyrus pyrifolia var. culta Species 0.000 claims 1
- 238000000034 method Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462024804P | 2014-07-15 | 2014-07-15 | |
| US62/024,804 | 2014-07-15 | ||
| PCT/US2015/040385 WO2016011035A2 (en) | 2014-07-15 | 2015-07-14 | Neutralizing anti-influenza b antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021018692A Division JP7209754B2 (ja) | 2014-07-15 | 2021-02-09 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523805A JP2017523805A (ja) | 2017-08-24 |
| JP2017523805A5 true JP2017523805A5 (enExample) | 2018-08-23 |
| JP6837434B2 JP6837434B2 (ja) | 2021-03-03 |
Family
ID=55079157
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523183A Active JP6837434B2 (ja) | 2014-07-15 | 2015-07-14 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2021018692A Active JP7209754B2 (ja) | 2014-07-15 | 2021-02-09 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2023001445A Active JP7453430B2 (ja) | 2014-07-15 | 2023-01-10 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2024034654A Pending JP2024069341A (ja) | 2014-07-15 | 2024-03-07 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021018692A Active JP7209754B2 (ja) | 2014-07-15 | 2021-02-09 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2023001445A Active JP7453430B2 (ja) | 2014-07-15 | 2023-01-10 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
| JP2024034654A Pending JP2024069341A (ja) | 2014-07-15 | 2024-03-07 | 抗ｂ型インフルエンザ抗体の中和及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10294292B2 (enExample) |
| EP (1) | EP3169407B1 (enExample) |
| JP (4) | JP6837434B2 (enExample) |
| CN (4) | CN113563462B (enExample) |
| AU (3) | AU2015289805B2 (enExample) |
| BR (1) | BR112017000640A2 (enExample) |
| CA (1) | CA2954780A1 (enExample) |
| MX (3) | MX392761B (enExample) |
| RU (2) | RU2711932C2 (enExample) |
| WO (1) | WO2016011035A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6535675B2 (ja) | 2013-10-02 | 2019-06-26 | メディミューン，エルエルシー | 抗ａ型インフルエンザ抗体の中和及びその使用 |
| CN113563462B (zh) | 2014-07-15 | 2024-08-13 | 免疫医疗有限责任公司 | 中和抗乙型流感抗体及其用途 |
| MX389708B (es) | 2015-06-01 | 2025-03-20 | Medimmune Llc | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. |
| SG11201805001UA (en) | 2016-01-13 | 2018-07-30 | Medimmune Llc | Method of treating influenza a |
| BR112022007923A2 (pt) * | 2019-10-28 | 2022-07-26 | Regeneron Pharma | Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza |
| CN112048006B (zh) * | 2020-09-08 | 2021-04-27 | 扬州大学 | 一种替代中和效力测定的elisa方法及其应用 |
| WO2023102398A2 (en) * | 2021-11-30 | 2023-06-08 | Sab, Llc | Ungulate-derived polyclonal immunoglobulin specific for influenza virus and uses thereof |
| CN118420751B (zh) * | 2022-07-09 | 2025-04-08 | 东莞市朋志生物科技有限公司 | 抗乙型流感病毒抗体、检测乙型流感病毒的试剂和试剂盒 |
| WO2026055183A1 (en) | 2024-09-03 | 2026-03-12 | Vir Biotechnology, Inc | Antiviral compositions and methods of using the same |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| WO1997008320A1 (en) | 1995-08-18 | 1997-03-06 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| US6093156A (en) | 1996-12-06 | 2000-07-25 | Abbott Laboratories | Method and apparatus for obtaining blood for diagnostic tests |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| AU8063798A (en) | 1997-06-19 | 1999-01-04 | Regents Of The University Of California, The | Secretory immunoglobulin produced by single cells and methods for making and using same |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| JP4528989B2 (ja) * | 1999-03-31 | 2010-08-25 | 学校法人慶應義塾 | インフルエンザウイルス・ヘマグルチニン結合性ペプチド |
| US8101553B1 (en) | 2000-02-22 | 2012-01-24 | Medical & Biological Laboratories Co., Ltd. | Antibody library |
| AU2001276842B2 (en) | 2000-06-28 | 2007-04-26 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20040110226A1 (en) | 2002-03-01 | 2004-06-10 | Xencor | Antibody optimization |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| CA2490423A1 (en) | 2002-06-21 | 2003-12-31 | Biogen Idec Inc. | Buffered formulations for concentrating antibodies and methods of use thereof |
| AU2003251809A1 (en) | 2002-07-11 | 2004-02-02 | The General Hospital Corporation | Polynucleotide and polypeptide fat metabolism regulators and uses thereof |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| JP4595810B2 (ja) | 2003-07-23 | 2010-12-08 | 富士レビオ株式会社 | 抗インフルエンザａ型ウイルスモノクローナル抗体及び該抗体を用いる免疫測定器具 |
| RU2390351C2 (ru) | 2003-08-11 | 2010-05-27 | Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити | Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| MY144906A (en) | 2005-10-21 | 2011-11-30 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
| MX2008009220A (es) | 2006-01-17 | 2008-10-10 | Biolex Therapeutics Inc | Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas. |
| WO2007109742A2 (en) | 2006-03-21 | 2007-09-27 | Weaver David T | Methods for humanizing antibodies and humanized antibodies made thereby |
| US7615220B2 (en) | 2006-04-07 | 2009-11-10 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-18 receptor |
| WO2007134327A2 (en) | 2006-05-15 | 2007-11-22 | Sea Lane Biotechnologies, Llc. | Neutralizing antibodies to influenza viruses |
| CA2663388C (en) | 2006-09-07 | 2017-01-17 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| WO2008054606A2 (en) | 2006-10-02 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| JP5601836B2 (ja) | 2006-11-08 | 2014-10-08 | マクロジェニックス ウエスト， インコーポレイテッド | Ｔｅｓ７およびｔｅｓ７に結合する抗体 |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
| CN102046654A (zh) | 2007-03-13 | 2011-05-04 | 胡马斯有限公司 | 针对甲型流感病毒h5n1株系的抗体 |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| ITTO20080398A1 (it) | 2008-05-27 | 2009-11-28 | Pomona Biotechnologies Llc | Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1 |
| ES2662519T3 (es) | 2008-07-25 | 2018-04-06 | Institute For Research In Biomedicine | Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| CA2736799A1 (en) | 2008-08-25 | 2010-03-11 | Burnham Institute For Medical Research | Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| US9534042B2 (en) * | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
| US9512182B2 (en) | 2010-12-13 | 2016-12-06 | University Of Utah Research Foundation | Vaccine antigens that direct immunity to conserved epitopes |
| US8961978B2 (en) * | 2011-07-14 | 2015-02-24 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses |
| CA2841551C (en) | 2011-07-18 | 2020-07-28 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| KR20140068205A (ko) | 2011-09-20 | 2014-06-05 | 마운트 시나이 스쿨 오브 메디슨 | 인플루엔자 바이러스 백신 및 이의 용도 |
| US9441019B2 (en) | 2011-09-23 | 2016-09-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Influenza hemagglutinin protein-based vaccines |
| EP2776061B1 (en) * | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
| CN104302321A (zh) * | 2011-12-05 | 2015-01-21 | 特瑞利斯生物科学有限责任公司 | 可用于被动流感免疫的抗体 |
| KR102050615B1 (ko) * | 2012-03-08 | 2019-11-29 | 얀센 백신스 앤드 프리벤션 비.브이. | 인플루엔자 b 바이러스들에 결합하고 중화할 수 있는 인간 결합 분자 및 그 용도 |
| AU2013345072B2 (en) | 2012-11-13 | 2017-12-07 | Genentech, Inc. | Anti-hemagglutinin antibodies and methods of use |
| KR20140118682A (ko) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| RU2536956C1 (ru) | 2013-08-05 | 2014-12-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт пульмонологии Федерального медико-биологического агентства" | Противовирусное однодоменное мини-антитело, нуклеотидная последовательность, экспрессирующий рекомбинантный вирусный вектор, фармацевтическая композиция и способ профилактики или терапии гриппа типа а |
| JP6535675B2 (ja) | 2013-10-02 | 2019-06-26 | メディミューン，エルエルシー | 抗ａ型インフルエンザ抗体の中和及びその使用 |
| CN113563462B (zh) | 2014-07-15 | 2024-08-13 | 免疫医疗有限责任公司 | 中和抗乙型流感抗体及其用途 |
| MX389708B (es) | 2015-06-01 | 2025-03-20 | Medimmune Llc | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. |
| SG11201805001UA (en) | 2016-01-13 | 2018-07-30 | Medimmune Llc | Method of treating influenza a |
| EP3419663A1 (en) | 2016-02-24 | 2019-01-02 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
-
2015
- 2015-07-14 CN CN202110634379.1A patent/CN113563462B/zh active Active
- 2015-07-14 CN CN201580038244.1A patent/CN106573154B/zh active Active
- 2015-07-14 WO PCT/US2015/040385 patent/WO2016011035A2/en not_active Ceased
- 2015-07-14 US US15/325,603 patent/US10294292B2/en active Active
- 2015-07-14 BR BR112017000640A patent/BR112017000640A2/pt not_active Application Discontinuation
- 2015-07-14 RU RU2017104638A patent/RU2711932C2/ru active
- 2015-07-14 CN CN202110634430.9A patent/CN113173990B/zh active Active
- 2015-07-14 AU AU2015289805A patent/AU2015289805B2/en active Active
- 2015-07-14 RU RU2020100073A patent/RU2739952C2/ru active
- 2015-07-14 CN CN202410982380.7A patent/CN119161468A/zh active Pending
- 2015-07-14 EP EP15821645.7A patent/EP3169407B1/en active Active
- 2015-07-14 JP JP2017523183A patent/JP6837434B2/ja active Active
- 2015-07-14 CA CA2954780A patent/CA2954780A1/en active Pending
- 2015-07-14 MX MX2017000595A patent/MX392761B/es unknown
-
2017
- 2017-01-13 MX MX2022006561A patent/MX2022006561A/es unknown
- 2017-01-13 MX MX2022006558A patent/MX2022006558A/es unknown
-
2019
- 2019-03-22 US US16/361,653 patent/US10519221B2/en active Active
- 2019-11-07 US US16/676,974 patent/US11174304B2/en active Active
-
2020
- 2020-09-15 AU AU2020233635A patent/AU2020233635B2/en active Active
-
2021
- 2021-02-09 JP JP2021018692A patent/JP7209754B2/ja active Active
- 2021-10-12 US US17/499,495 patent/US11787853B2/en active Active
-
2023
- 2023-01-10 JP JP2023001445A patent/JP7453430B2/ja active Active
- 2023-09-08 US US18/463,736 patent/US12325740B2/en active Active
-
2024
- 2024-03-07 JP JP2024034654A patent/JP2024069341A/ja active Pending
- 2024-04-08 AU AU2024202231A patent/AU2024202231A1/en active Pending
-
2025
- 2025-05-08 US US19/202,812 patent/US20250263470A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240425617A1 (en) | Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies | |
| JP2017523805A5 (enExample) | ||
| US11926657B2 (en) | Neutralizing anti-influenza binding molecules and uses thereof | |
| JP2016538876A5 (enExample) | ||
| RU2017104638A (ru) | Нейтрализующие антитела к вирусу гриппа B и пути их применения | |
| JP6371222B2 (ja) | インフルエンザの受動免疫用抗体 | |
| CN115515976A (zh) | 冠状病毒抗体 | |
| JP2018514193A5 (enExample) | ||
| WO2018213097A1 (en) | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof | |
| WO2026021428A1 (en) | Anti-neuraminidase antibodies and uses thereof | |
| HK40061503B (zh) | 中和抗流感结合分子及其用途 | |
| HK40061503A (en) | Neutralizing anti-influenza binding molecules and uses thereof | |
| HK40069730A (en) | Neutralizing anti-influenza binding molecules and uses thereof | |
| WO2024108088A1 (en) | Lag-3 and pd-1/lag-3-antibodies | |
| HK40040395B (zh) | 用於治疗癌症的组合物和方法 | |
| HK1250725B (zh) | 中和抗流感结合分子及其用途 | |
| HK1253092B (en) | Neutralizing anti-influenza binding molecules and uses thereof |